According to a Bloomberg article, the Federal Trade Commission (FTC), which monitors advertising claims, requested the Food and Drug Administration (FDA) to reevaluate its regulatory approach on homeopathic products. The agency has never evaluated them for safety or efficacy, but it oversees manufacturing practices.
The FTC filed official comments that said it is "concerned" that the FDA's policy on homeopathy conflicts with the FTC's requirement that medical advertising claims be supported by evidence, the article said. The split "may harm consumers and create confusion for advertisers," the agency said.
Read the Bloomburg article
